scispace - formally typeset
Search or ask a question
Author

Ryanne W. Lieshout-Krikke

Bio: Ryanne W. Lieshout-Krikke is an academic researcher. The author has contributed to research in topics: Hepatitis B virus & Public health. The author has an hindex of 9, co-authored 18 publications receiving 161 citations.

Papers
More filters
Journal ArticleDOI
TL;DR: Some PCs have already been transfused at the moment of a positive signal in continued cultures in the BacT/Alert system, and it is unclear, however, whether these PCs are associated with more transfusion reactions.
Abstract: Background The BacT/ALERT system for bacterial monitoring of platelet concentrates (PCs) was introduced in the Netherlands in 2001. Samples are cultured for 7 days, and as a result of the short shelf-life of PCs, they are usually released as ‘negative to date’. Therefore, some of the PCs have already been transfused at the moment of a positive signal in continued cultures in the BacT/Alert. It is unclear, however, whether these PCs are associated with more transfusion reactions. Methods During a 2-year period clinical data were collected from all patients who received PCs released as ‘negative to date’ but with a positive bacterial culture after being transfused. Results Data of 158 patients who received PCs with confirmed positive bacterial culture tests were analysed. Two patients developed a transfusion reaction. In both PCs, Propionibacterium was cultured. The imputability as related to the transfusion was classified as unlikely in both patients. Conclusion Two of 158 transfusions of PCs released as ‘negative to date’, but with a confirmed positive BacT/ALERT result, were initially associated with transfusion reactions. However, the imputability of both reactions was low.

29 citations

Journal ArticleDOI
TL;DR: Blood services around the world are surveyed to assess the different research programmes related to COVID‐19 planned or in progress and to measure seroprevalence in donors to inform public health policy.
Abstract: BACKGROUND AND OBJECTIVES: While coronavirus (COVID-19) is not transfusion-transmitted, the impact of the global pandemic on blood services worldwide is complex. Convalescent plasma may offer treatment, but efficacy and safety are not established. Measuring seroprevalence in donors would inform public health policy. Here, we survey blood services around the world to assess the different research programmes related to COVID-19 planned or in progress. MATERIALS AND METHODS: Blood collection services were surveyed in June 2020 to determine whether they were participating in serosurveys or convalescent plasma collection and clinical trials. RESULTS: A total of 48 countries (77% of those contacted) responded. Seroprevalence studies are planned or in progress in 73% of countries surveyed and in all continents, including low- and middle-income countries. Most aimed to inform public health policy. Convalescent plasma programmes have been initiated around the globe (79% of surveyed), about three quarters as clinical trials in high-, middle- and low-income countries. CONCLUSION: Blood services around the world have drawn upon their operational capacity to provide much-needed seroprevalence data to inform public health. They have rapidly implemented preparation of potential treatment when few treatments are available and mostly as clinical trials. At the same time, they must continue to provide blood products for recipients despite challenges of working in a state of emergency. It is important to track and coordinate research efforts across jurisdictions to gain a composite evidence-based view that will influence future practice and preparative strategies.

21 citations

Journal ArticleDOI
TL;DR: The proportion of incident transfusion‐transmissible infections in candidate donors, in first‐time donors, and in repeat donors was compared to explore the potential value of predonation screening of candidate donors.

20 citations

Journal ArticleDOI
TL;DR: Introduction of HBV DNA screening of Dutch blood donors enabled the characterization of HBsAg-negative HBV infection in healthy persons and a comparison of the HBV genomes involved, finding screening of blood donors forHBV DNA and HBV core antibodies seems to cover all stages and variants of HBv infection.
Abstract: Hepatitis B virus (HBV) surface antigen (HBsAg) is a reliable marker for HBV infection, but HBsAg-negative forms of HBV infection occur. The introduction of HBV DNA screening of Dutch blood donors, which were not preselected for absence of HBV core antibodies, enabled the characterization of HBsAg-negative HBV infection in healthy persons and a comparison of the HBV genomes involved. The screening of 4.4 million Dutch blood donations identified 23 HBsAg-negative, HBV DNA-positive persons. Serological testing of the index donations, follow-up samples and archived earlier samples was performed to determine the nature of each HBV DNA-only case. Despite low viral loads HBV DNA could be sequenced in 14 out of 23 donors, allowing HBV genotyping and the analysis of mutations in the HBV surface gene. Four types of HBsAg-negative HBV infection were detected: infection in the early stage before occurrence of HBsAg; suppressed infection after vaccination; HBV genotype G infection with decreased HBsAg production; and chronic occult (HBsAg negative) HBV infection. In the donors with occult HBV genotype D infection the HBV surface gene showed multiple “escape” mutations in the HBsAg a-determinant and CTL epitopes, while in an occult genotype A case the surface gene showed no mutations. HBsAg-negative forms of HBV infection in healthy blood donors explain the ongoing transmission of HBV via blood transfusion, if donor screening is limited to HBsAg. The screening of blood donors for HBV DNA and HBV core antibodies seems to cover all stages and variants of HBV infection.

20 citations

Journal ArticleDOI
TL;DR: This study describes the lookback results for repeat donors with an “HBV DNA‐only” test result (HBVDNA‐positive and HBsAg‐negative) and explains the rationale behind the introduction of HBV DNA testing.

16 citations


Cited by
More filters
01 Sep 1999
TL;DR: Attention is drawn to the following places, which may be of interest for search: Transmission systems for measured values, control or similar signals.
Abstract: References Informative references Attention is drawn to the following places, which may be of interest for search: Transmission systems for measured values, control or similar signals G08C Speech analysis or synthesis G10L Coding, decoding or code conversion H03M Broadcast communication H04H Multiplex communication H04J Secret communication H04K Transmission of digital information H04L Telephonic communication H04M Pictorial communication H04N Wireless communication networks H04W

283 citations

Journal ArticleDOI
TL;DR: Occult hepatitis B virus (HBV) infection (OBI) is identified in 1:1000 to 1:50,000 European blood donations and the infectivity of blood products from OBI donors is determined.

127 citations

Journal ArticleDOI
TL;DR: HBV DNA integration influencing hepatocyte cell cycle and tumour development, production of pro-oncogenic proteins such as HBx protein and mutated surface proteins, and persistent low grade hepatic necroinflammation contributing to liver fibrosis and cirrhosis are the proposed pathogenetic mechanisms of OBI-related HCC.

114 citations

Journal ArticleDOI
TL;DR: Although not currently part of routine clinical care, evaluation of genotype and viral variants may provide useful adjunctive information in predicting risk about liver related morbidity in patients with CHB.
Abstract: The Hepatitis B Virus (HBV) has a worldwide distribution and is endemic in many populations. It is constantly evolving and 10 genotypic strains have been identified with varying prevalences in different geographic regions. Numerous stable mutations in the core gene and in the surface gene of the HBV have also been identified in untreated HBV populations. The genotypes and viral variants have been associated with certain clinical features of HBV related liver disease and Hepatocellular carcinoma. For example Genotype C is associated with later hepatitis B e antigen (HBeAg) seroconversion, and more advanced liver disease. Genotype A is associated with a greater risk of progression to chronicity in adult acquired HBV infections. Genotype D is particularly associated with the precore mutation and HBeAg negative chronic hepatitis B (CHB). The genotypes prevalent in parts of West Africa, Central and South America, E, F and H respectively, are less well studied. Viral variants especially the Basal Core Promotor mutation is associated with increased risk of fibrosis and cancer of the liver. Although not currently part of routine clinical care, evaluation of genotype and viral variants may provide useful adjunctive information in predicting risk about liver related morbidity in patients with CHB.

104 citations